Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 111,367 | 112,546 | 99,176 | 114,362 | 204,618 |
| Receivables | 446,025 | 400,619 | 388,072 | 412,898 | 402,235 |
| Inventories | 391,011 | 367,823 | 354,975 | 332,565 | 301,638 |
| Other current assets | 201,043 | 220,489 | 216,636 | 183,000 | 181,281 |
| TOTAL | $1,149,446 | $1,101,477 | $1,058,859 | $1,042,825 | $1,089,772 |
| Non-Current Assets | |||||
| PPE Net | 665,439 | 649,474 | 612,405 | 594,224 | 593,457 |
| Intangibles | 94,361 | 459,467 | 455,260 | 456,122 | 466,156 |
| Other Non-Current Assets | 899,152 | 536,347 | 513,543 | 514,014 | 443,304 |
| TOTAL | $1,658,952 | $1,645,288 | $1,581,208 | $1,564,360 | $1,502,917 |
| Total Assets | $2,808,398 | $2,746,765 | $2,640,067 | $2,607,185 | $2,592,689 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 74,986 | 74,982 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 117,709 | 110,221 | 110,144 | 127,262 | 120,881 |
| Accrued Expenses | 403,595 | 433,662 | 405,992 | 387,510 | 409,555 |
| TOTAL | $1,065,629 | $1,235,803 | $1,189,945 | $1,166,547 | $971,341 |
| Non-Current Liabilities | |||||
| Long Term Debt | 696,362 | 694,387 | 760,814 | 767,995 | 773,381 |
| Deferred Revenues | 37,839 | 37,938 | 40,809 | 40,775 | 40,905 |
| Other Non-Current Liabilities | 169,041 | 168,826 | 164,081 | 167,818 | 161,479 |
| TOTAL | $901,668 | $902,225 | $974,123 | $983,630 | $981,550 |
| Total Liabilities | $1,967,297 | $2,138,028 | $2,164,068 | $2,150,177 | $1,952,891 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 83,005 | 82,903 | 82,817 | 83,254 | 84,007 |
| Common Shares | 10,732 | 10,719 | 10,709 | 10,707 | 10,700 |
| Retained earnings | 3,813,583 | 3,599,529 | 3,427,322 | 3,246,384 | 3,114,405 |
| Other shareholders' equity | -71,117 | -72,726 | -75,560 | -62,792 | -41,332 |
| TOTAL | $841,101 | $608,737 | $475,999 | $457,008 | $639,798 |
| Total Liabilities And Equity | $2,808,398 | $2,746,765 | $2,640,067 | $2,607,185 | $2,592,689 |